Association between serum fibroblast growth factor 21 level and sight-threatening diabetic retinopathy in Chinese patients with type 2 diabetes

Shi Jin, Ning Xia, Lingling Han

ABSTRACT

Introduction We conducted this cross-sectional study to explore the relationship between serum fibroblast growth factor 21 (FGF21) level and sight-threatening diabetic retinopathy (STDR).

Research design and methods A total of 654 patients with type 2 diabetes were recruited. Diabetic retinopathy (DR) was evaluated by the bilateral retinal photography, and patients were assigned into groups of no DR (NDR) (n=345, 52.75%), non-sight-threatening diabetic retinopathy (NSTR) (n=207, 31.65%), involving patients with mild or moderate non-proliferative retinopathy (NPDR) and STDR (n=102, 15.60%), including those with severe NPDR or proliferative diabetic retinopathy (PDR).

Serum FGF21 levels were quantified by a sandwich ELISA. Patients were divided into quartiles according to their serum FGF21 level.

Results There was a significant difference in serum FGF21 level among the three groups of patients (p<0.01). Compared with other quartiles (Q1–Q3), the patients in Q4 had a higher prevalence of DR and STDR (p<0.05). Compared with Q1, a positive association was observed between serum FGF21 level and DR and STDR (p<0.01). After adjusting for age, gender and other risk factors, serum FGF21 level in Q4 was found to be associated with increased risk of DR and STDR (p<0.01). Serum FGF21 level was noted as an independent risk factor for DR and STDR (p<0.01). Serum FGF21 level >478.76 pg/mL suggested the occurrence of DR and that level >554.69 pg/mL indicated STDR (p<0.01).

Conclusions Serum FGF21 level was a biomarker for the risk of developing DR or STDR. The risk of STDR increased when the serum FGF21 level of patients with type 2 diabetes was >554.69 pg/mL.

INTRODUCTION

With the improvement of people’s living standards and the change of their lifestyle, diabetes has become one of the most important chronic non-communicable diseases threatening the global health. According to the latest statistics released in 2019 by the International Diabetes Federation, it is estimated that 463 million people have diabetes and this number is projected to reach 578 million by 2030, and 700 million by 2045. Diabetes is becoming one of the fastest growing global health challenges in the 21st century and has reached alarming levels; at present, nearly half a billion people are living with diabetes worldwide. In 2019, China included the largest number of adults with diabetes aged 20–79 years, and this trend is predicted to remain so in 2030 and 2045.

Diabetic retinopathy (DR) is one of the most common microvascular complications of diabetes and has become the leading cause of new blindness in adults aged 20–74 years.

It was estimated that 23% of Chinese patients with diabetes have retinal complications and there was a lack of effective DR screening methods in inland areas. DR is characterized...
Pathophysiology/complications

by blurred vision, vision loss and even blindness. Several studies have shown that the duration of diabetes, blood glucose control level and blood pressure are major independent risk factors for the occurrence and development of DR. It was recommended that patients with type 2 diabetes should receive comprehensive eye examination immediately after diagnosis, and the frequency of review should not be less than once every 2 years. The frequency of examination should be increased if there is any progression of retinopathy or vision loss. Because of the shortage of obvious symptoms or signs of early DR and the lack of sufficient equipment or ophthalmologists, there was a great difficulty to early diagnosis and early treatment of DR. Therefore, finding a more effective, convenient and economical means of screening DR has become an urgent medical and health problem that significantly requires scholars’ attention.

Fibroblast growth factor 21 (FGF21) is a polypeptide with 210 amino acids, which is preferentially produced in the liver and plays a significant role in atherosclerosis formation, regulating glucose and lipid metabolism and insulin sensitivity. Several epidemiological studies reported the increased serum level of FGF21 in patients with obesity, diabetes and metabolic syndrome. Meanwhile, its association with cardiovascular events has received increasing attention. It was reported that FGF21 was closely associated with acute myocardial infarction and lower extremity atherosclerotic disease. However, a limited number of studies have discussed the association between FGF21 and DR. The current research was conducted to assess the difference in the serum FGF21 level in patients with and without sight-threatening diabetic retinopathy (STDR), and to evaluate the value of this serum marker for screening STDR in Chinese patients with type 2 diabetes.

METHODS

Study population

A number of 654 outpatients admitted to the Fourth Affiliated Hospital of China Medical University from January 2018 to October 2019 were included in this study, who were diagnosed with type 2 diabetes mellitus (T2DM) according to the 1999 WHO criteria and the 2012 American Diabetes Association standards of medical care in diabetes. Those patients with type 1 diabetes or specific types of diabetes, acute complications of diabetes, fundus lesions owing to orbital tumor, trauma, malignant hypertension or other definite causes and secondary nephropathy caused by acute glomerulonephritis, pyelonephritis, nephrolithiasis and so on were excluded. In total, 347 males (56.88%) and 307 females (53.06%) were enrolled with a mean age of 57.90±11.05 years and the mean duration of diabetes was 8.74±6.25 years.

Data collection and anthropometric measurement

Data related to the patients’ sex, age, duration of diabetes and history of smoking, drinking, coronary artery disease and cerebral apoplexy were collected. A patient’s height was measured to the nearest centimeter. Weight was determined with a traditional spring balance that was kept on a firm horizontal surface. The body mass index (BMI) was calculated as the weight in kilograms divided by height in meters squared. Blood pressure was measured by the same nurse using a mercury sphygmomanometer for three times and then averaged.

Laboratory measurements

Blood samples were collected from an antecubital vein for measuring the levels of total cholesterol, triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol, blood urea nitrogen (BUN), serum creatinine (Cr), uric acid, fasting plasma glucose and 2-hour postprandial blood glucose by an enzymatic method with an automatic biochemical analyzer (Cobas c701; Roche, Basel, Switzerland). Glycosylated hemoglobin (HbA1c) level was determined by high-pressure liquid chromatography using the Variant II machine (Bio-Rad Laboratories, Hercules, California, USA). Glycosylated albumin (GA) level was determined by the liquid enzymatic assay using the Glamour 2000 automatic biochemical analyzer (MD, Silicon Valley, California, USA). The serum FGF21 level was determined by ELISA (ab222506, Abcam, Shanghai, China). The intra-assay and inter-assay variations were 7.8% and 9.1%, respectively. Continuous dilution of recombinant FGF21 was used as the standard. Repeated measurements were carried out for all samples. All the patients were divided into quartiles according to their serum FGF21 level (pg/mL) as follows: quartile 1 (Q1, FGF21 <388), quartile 2 (Q2, 388 ≤ FGF21 <455), quartile 3 (Q3, 455 ≤ FGF21 <579) and quartile 4 (Q4, FGF21 ≥580).

Ophthalmic examination and grading of DR

All participants received eye examinations by the same experienced ophthalmologist and fundus photography was performed using a 45-degree 6.3-megapixel digital non-mydriatic camera (Canon CR-45NM, Lake Success, New York, USA). The photographs were graded according to the International Classification of Diabetic Retinopathy scale: (i) no changes in DR; (ii) mild non-proliferative diabetic retinopathy (NPDR); (iii) severe NPDR; (iv) moderate NPDR; (v) proliferative diabetic retinopathy (PDR). The degree of DR was determined according to the grading in the worse eye. Then, the patients were divided into three groups: no DR (NDR) (n=345, 52.75%), non-sight-threatening diabetic retinopathy (NSTR) (n=207, 31.65%), involving patients with mild or moderate NPDR and STDR (n=102, 15.60%), including those with severe NPDR or PDR.

Statistical analysis

SPSS V.16.0 software (IBM, Armonk, New York, USA) was used to carry out statistical analysis. Data were expressed as mean±SD for continuous variables and percentages (%) for categorical variables. Differences among the
groups were detected using analysis of variance test or Kruskal-Wallis test as appropriate for measurement data, as well as the χ² test for categorical data. Multivariable logistic regression analysis was performed to evaluate the OR and associated factors. We calculated the OR with 95% CI of DR associated with FGF21 in three logistic regression models: a non-adjusted model; age-adjusted, sex-adjusted model and a multivariable regression model adjusted for all variables (p<0.05). After the analysis of correlation, receiver operating characteristic (ROC) curve was used to find the cut-point of FGF21 to predict DR and STDR. Two-tailed p<0.05 was considered statistically significant.

RESULTS
Comparing the patients’ clinical characteristics
Between January 2018 and October 2019, a total of 654 patients with type 2 diabetes were enrolled in this study and all the patients were divided into three groups according to the results of fundus examination, including NDR (n=345, 52.75%), NSTDR (n=207, 31.76%) and STDR (n=102, 15.60%). Overall, the study population (347 males and 307 females) had a mean age of 57.90±11.05 years, the duration of T2DM 8.74±6.25 years and the median serum level of FGF21 was 450.50±101.46 pg/mL, with an IQR of 190.05–545.55 pg/mL.

The patients’ demographic and clinical characteristics are summarized in Table 1. There were significant differences in duration of diabetes, blood glucose level, renal function and serum FGF21 level among the three groups of patients. Compared with patients in NDR group, those in NSTDR and STDR groups had significantly longer duration of diabetes and higher serum levels of HbA1c, GA, Cr and FGF21 (572.7±79.5, 625.8±83.7 vs 326.8±81.6 pg/mL). Besides, compared with patients in NSTDR group, those in STDR group had remarkably longer duration of diabetes and higher serum levels of BUN, Cr and FGF21 (625.8±83.7 vs 572.7±79.5 pg/mL).

Table 1 Comparison of clinical characteristics and FGF21 among three DR levels

| Characteristics      | NDR       | NSTDR     | STDR      | P value |
|----------------------|-----------|-----------|-----------|---------|
| Case (male/female)   | 345 (185/160) | 207 (107/100) | 102 (55/47) | /       |
| Age (year)           | 57.11±11.99 | 58.41±10.13 | 58.93±10.71 | 0.190   |
| Duration of diabetes (year) | 7.11±5.76 | 9.95±6.24* | 11.81±7.27† | 0.000   |
| BMI (kg/m²)          | 25.28±3.64 | 25.31±3.14 | 25.11±3.74 | 0.679   |
| SBP (mm Hg)          | 128.19±14.22 | 127.65±14.53 | 128.79±15.21 | 0.544   |
| DBP (mm Hg)          | 78.84±7.82 | 77.59±7.31 | 78.61±7.97 | 0.678   |
| Smoking (%)          | 31.2      | 36.4      | 26.0      | 0.226   |
| Drinking (%)         | 17.4      | 19.2      | 15.4      | 0.423   |
| Coronary artery disease (%) | 8.7     | 10.2      | 14.9      | 0.241   |
| Cerebral infarction (%) | 6.2     | 9.6       | 8.1       | 0.277   |
| FPG (mmol/L)         | 7.79±2.61 | 8.49±2.25 | 8.07±2.66 | 0.118   |
| PPG (mmol/L)         | 12.53±4.39 | 13.14±4.57 | 12.32±4.61 | 0.393   |
| HbA1c (%)            | 7.73±1.88 | 8.28±1.77* | 8.49±1.93* | 0.000   |
| GA (%)               | 20.47±6.32 | 22.18±5.74* | 22.79±6.49* | 0.000   |
| BUN (mmol/L)         | 5.24±1.29 | 5.31±1.15 | 6.03±2.02† | 0.008   |
| Cr (μmol/L)          | 62.4±15.81 | 65.56±15.28* | 71.55±20.84† | 0.001   |
| UA (μmol/L)          | 315.58±82.92 | 306.27±79.05 | 332.24±84.47 | 0.071   |
| TC (mmol/L)          | 4.9±1.05  | 4.8±1.03  | 5.1±1.24  | 0.210   |
| TG (mmol/L)          | 1.79±1.46 | 1.99±1.51 | 1.81±1.50 | 0.140   |
| HDL-C (mmol/L)       | 1.12±0.27 | 1.08±0.25 | 1.15±0.32 | 0.100   |
| LDL-C (mmol/L)       | 2.95±0.86 | 2.83±0.79 | 3.02±0.77 | 0.177   |
| FGF21 (pg/mL)        | 326.8±81.6 | 572.7±79.5* | 625.8±83.7† | 0.000   |

*P<0.01 vs NDR. †P<0.01 vs NSTDR.

BMI, body mass index; BUN, blood urea nitrogen; Cr, creatinine; DBP, diastolic blood pressure; FGF21, fibroblast growth factor 21; FPG, fasting plasma glucose; GA, glycosylated albumin; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NDR, no diabetic retinopathy; NSTDR, non-sight threatening diabetic retinopathy; PPG, postprandial blood glucose; SBP, systolic blood pressure; STDR, sight-threating diabetic retinopathy; TC, total cholesterol; TG, triglyceride; UA, uric acid.

Association of serum FGF21 level with DR and STDR
In order to compare prevalence of DR and investigate association between DR and serum FGF21 level, we also divided all the patients into groups of Q1–Q4 according to their serum FGF21 level. As shown in Figure 1, with the increase of serum FGF21 level, the prevalence of DR and STDR increased gradually. Compared with Q1
and Q2 groups, the patients in Q3 and Q4 groups had significantly higher prevalence of DR and STDR (DR prevalence (%): 28.15, 40.17, 52.94 and 67.36, respectively; STDR prevalence (%): 4.62, 7.95, 17.65 and 31.38, respectively; all p<0.05). Table 2 shows the association between serum FGF21 level and DR severity. Compared with Q1 group, a significant positive association was clearly observed between serum FGF21 level and DR in Q3 group (OR 4.63; 95% CI 1.09 to 6.44) and Q4 (OR 6.98; 95% CI 1.98 to 11.50) in non-adjusted model. In the age-adjusted, sex-adjusted model and the multivariable regression model, the significant association could be observed (all p<0.05). The similar results appeared in models of STDR. The positive association between serum FGF21 level and STDR was significant in Q3 and Q4 groups compared with Q1 group (reference) in the three models (all p<0.05). Besides, the association between serum FGF21 level and STDR was stronger than that of DR. Compared with Q1 group, the multivariable OR (95% CI) of STDR in Q4 group was 10.22 (5.25 to 15.06) and 9.10 (5.70 to 15.79) in the age-adjusted, sex-adjusted model and the multivariable regression model, respectively (both p<0.01).

**DISCUSSION**

In the present study, we aimed at investigating the relationship between serum FGF21 level and DR, as well as evaluating the predictive value of serum FGF21 level for STDR in patients with type 2 diabetes. The results revealed that serum FGF21 level was significantly associated with the severity of DR and serum FGF21 level >554.69 pg/mL predicted over-eight-times elevated risk of the presence of STDR. This suggests that serum FGF21 level might be a potential indicator of the progression of severe DR in Chinese patients with type 2 diabetes.

Differences in serum FGF21 level between healthy volunteers and patients with type 2 diabetes were first observed in patients with abnormal glucose level and lipid metabolism. The baseline serum FGF21 levels were found significantly higher in patients with obesity, diabetes and metabolic syndrome than those in healthy subjects. A community-based study recruited 232 Chinese patients and found that overweight individuals or individuals with obesity had significantly higher plasma FGF21 levels than normal-weight individuals, and plasma FGF21 level was significantly associated with a number of indicators, such as BMI, waist circumference, waist-to-hip ratio and body fat content. A follow-up study of 1900 adults reported a remarkable increase in serum FGF21 levels in patients with type 2 diabetes and prediabetes. Gao et al demonstrated that higher serum FGF21 levels were positively associated with metabolic syndrome in patients with T2DM and significantly positively correlated with body
In the present study, we recruited 654 patients with type 2 diabetes and divided them into three groups according to the results of fundus examination, including NDR, NSTD and STDR. Overall, the median serum level of FGF21 was 449.47±101.46 pg/mL, which was consistent with previous findings and even higher than that in healthy controls. Meanwhile, there was a significant difference in serum FGF21 level among patients with or without DR. The serum FGF21 level was consistent with the degree of DR.

Numerous epidemiological studies previously reported that age, duration of diabetes, hyperglycemia, hypertension, hyperlipidemia were summarized as the traditional risk factors for DR, which was consistent with results of the present research. In our research, serum FGF21 level was the independent risk factors for DR and STDR. And the prevalence of DR and STDR increased gradually with the increased serum FGF21 level. This close relationship between serum FGF21 level and DR was also reported by other researches. A cross-sectional study recruited 117 patients with diabetes and 68 healthy controls. It was revealed that serum FGF21 concentrations in patients with PDR or NPDR were significantly higher than those in patients without DR. Meanwhile, there was a significant difference in serum FGF21 level among patients with or without DR. The serum FGF21 level was consistent with the degree of DR.

### Table 2

| FGF21 (pg/mL) | OR (95% CI) | P value | OR (95% CI) | P value |
|---------------|-------------|---------|-------------|---------|
| Age- adjusted, sex-adjusted OR | 2.21 (0.83 to 1.76) | 0.01 | 4.63 (1.09 to 6.44) | 0.00 |
| Multivariable-adjusted OR | 2.34 (0.88 to 1.90) | 0.04 | 5.76 (1.21 to 2.80) | 0.00 |
| P | 0.19 | 0.002 | 0.00 | 0.00 |
| Multivariable-adjusted OR | 4.65 (1.06 to 17.62) | 0.01 | 4.74 (1.13 to 17.52) | 0.00 |
| P | 0.00 | 0.002 | 0.00 | 0.00 |

DR, diabetic retinopathy; FGF21, fibroblast growth factor 21; STDR, sight-threatening diabetic retinopathy.

### Table 3

| Independent factors | DR | STDR |
|---------------------|----|------|
| FGF21               | 0.73 | 0.89 |
| Age                 | 0.05 | 0.12 |
| Diabetes duration   | 0.05 | 0.04 |
| High-density lipoprotein cholesterol | 0.02 | 0.02 |

**OR analysis of FGF21 for the risk of DR and STDR**

| FGF21 (pg/mL) | SE | Wald | P value |
|---------------|----|------|---------|
| Age- adjusted, sex-adjusted OR | 0.73 | 0.29 | 7.66 <0.01 |
| Multivariable-adjusted OR | 0.05 | 0.02 | 12.07 <0.01 |
| P | 0.00 | 0.002 | 0.00 | 0.00 |
| Multivariable-adjusted OR | 0.05 | 0.02 | 4.03 0.04 |
| P | 0.00 | 0.002 | 0.00 | 0.00 |

**OR analysis of FGF21 for the risk of DR and STDR**

Fat content and TG level in these subjects. In addition, serum FGF21 level was previously found to be strongly associated with age, insulin resistance and adverse lipid profiles. In the present study, we recruited 654 patients with type 2 diabetes and divided them into three groups according to the results of fundus examination, including NDR, NSTD and STDR. Overall, the median serum level of FGF21 was 449.47±101.46 pg/mL, which was consistent with previous findings and even higher than that in healthy controls. Meanwhile, there was a significant difference in serum FGF21 level among patients with or without DR. The serum FGF21 level was consistent with the degree of DR.
research, compared with the patients in Q1 group (reference), patients in Q4 group had significantly higher risks of DR and STDR after adjusting for all the associated factors. ROC analysis further revealed that when the serum FGF21 level was >554.69 pg/mL, the patients with type 2 diabetes had over eight-time increased risk of STDR.

Several researches have concentrated on the association between serum FGF21 level and DR, while further study needs to be conducted due to controversial outcomes. The Fen fibrate Intervention and Event Lowering in Diabetes study that recruited 9697 participants showed that higher serum FGF21 level was associated with a high risk of baseline total microvascular disease. However, when those with microvascular disease were separately studied, serum FGF21 level was only correlated to nephropathy, and it had no association with retinopathy or other microvascular diseases.20 A number of scholars further studied the relationship between serum FGF21 level and DR, and found that cases with DR had a significantly higher serum FGF21 level than those without DR.17 21 Jung et al reported a different U-shaped relationship between serum FGF21 level and prevalence of DR.22 This discrepancy might result from the difference in patients’ characteristics, such as age, blood glucose level, lipoprotein level and so on. Numerous researches pointed out that the mentioned discrepancy might be related to a relatively small sample size. The strength of our research was a larger population (654 patients) and first reported the relationship between serum FGF21 level and a subtype of DR, namely STDR.

FGF21 is a new endocrine hormone mainly produced by liver and adipose tissue, and its expression is regulated by peroxisome proliferator-activated receptor (PPAR)α and PPARγ, respectively. FGF21 could be secreted into blood and has physiological functions, mainly includeing increasing the production of gluconeogenesis and ketone bodies under starvation and increasing insulin sensitivity in the postprandial state. The research focused on mechanism behind the association between serum FGF21 level and DR was relatively infrequent. However, based on the previous research related to FGF21, we could speculate the mechanism possible for the elevated serum FGF21 level with DR might include a compensatory mechanism to counteract metabolic stress and vascular endothelial dysfunction.23 24 It was revealed that there existed FGF21 resistance in obesity or cardiovascular failure.25 26 The term ‘FGF21 resistance’ was first used to describe increased circulating FGF21 levels concomitant to decreased FGF21 receptor complex expression in white adipose tissue of mice with obesity. Previous studies found that in insulin-resistant mice, the expression of FGF21 in liver and adipose tissue is increased, while the expression of FGF21 receptor is decreased, suggesting the existence of FGF21 resistance.23 Nowadays, several lines of evidence showed that the vascular system might be a target for FGF21. For example, FGF21 protects against atherosclerosis by inducing adiponectin to inhibit neointima formation and macrophage inflammation in blood vessels and suppresses hepatic cholesterol synthesis to attenuate hypercholesterolemia.27 FGF21 also acts adipocytes and renal cells to promote metabolism of angiotensin II and to mitigate hypertension and vessel injury.28 Lei Ying et al reported that FGF21 improves dilation of aorta in both type 1 diabetes and type 2 diabetes mice, probably via CaMKK2/AMPKα-mediated suppression of oxidative stress and activation of endothelial nitric oxide synthase.29 Based on these findings, we propose that the mechanism of increased FGF21 levels in DR is similar to

Figure 2 Receiver operating characteristic curve analysis of fibroblast growth factor-21 (FGF21) for (A) diabetic retinopathy, area under the curve (AUC)=0.617 (p=0.001), 95% CI 0.581 to 0.652. The optimal cut-off point of serum FGF21 level was 478.76 pg/mL (Youden Index, 0.19; sensitivity, 42.4%; specificity, 76.2%). (B) Sight-threatening diabetic retinopathy, AUC=0.791 (p=0.001), 95% CI 0.746 to 0.836. The optimal cut-off point of serum FGF21 level was 554.69 pg/mL (Youden Index, 0.21; sensitivity, 67.3%; specificity, 84.6%).
those observed in hyperglycemia-associated resistance to adiponectin. In response to endothelial dysfunction, serum FGF21 might be compensatorily increased to repair microvascular lesions involved in retinopathy.

According to the 2012 American Diabetes Association standards of medical care in diabetes, timely laser photocoagulation therapy based on high-quality fundus photographs can be used to reduce the risk of vision loss in patients with high-risk DR. Hence, ADA repeatedly emphasized that less-frequent eye examinations (every 2–3 years) should be performed by an ophthalmologist who is expert in diagnosing the presence of DR. To meet this demand, the use of retinal photography in remote reading by experts is recommended in areas where advanced medical equipment or qualified eye care professionals are not existed. However, the measurement of FGF21 in serum samples is efficient, common and easy to be expanded and popularized in the community hospitals. Therefore, the FGF21 assay can benefit more populations and prompt the necessity to take further eye examinations and therapies. What is important is the fact that the close relationship between serum FGF21 level and DR provided a new pathway for the therapy of DR in the future.

Limitations

One of the limitations of the present study was that no cause-and-effect relationship between serum FGF21 level and DR or STD is could be drawn due to cross-sectional nature of this study. Second, the sample size was relatively small, especially the number of cases with STD. Moreover, this was a single-center study, which limited its clinical efficacy. A longitudinal, multicenter follow-up study should be carried out to verify predictive value of serum FGF21 level for DR and STD. Third, the generalizability of our results to other ethnic groups with type 2 diabetes remained elusive.

CONCLUSIONS

Serum FGF21 level was found to be positively associated with the severity of DR in Chinese patients with type 2 diabetes. Additionally, serum FGF21 level is a potential indicator of STD. The serum FGF21 level >554.69 pg/mL indicates over eight-time enhancement of STD occurrence.

Acknowledgements

The authors would like to thank TopEdit (www.topeditsci.com) for the linguistic assistance provided during the preparation of this manuscript.

Contributors

LH conceived the study. SJ designed the research. SJ and NX conducted the experiments. NX and SJ collected clinical data. NX and SJ analyzed the data. SJ wrote the manuscript. LH revised the manuscript. All authors approved this submission.

Funding

This study was financially supported by Liaoning Natural Science Fund Plan Guidance Project (grant no. 2019-2D-0774).

Competing interests

None declared.

Patient consent for publication

Not required.

Ethics approval

The study was approved by the Human Research and Ethics Committee of the Fourth Affiliated Hospital of China Medical University and the Fourth People’s Hospital of Shenyang, and was conducted in accordance with the Declaration of Helsinki. All the procedures were performed in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Declaration of Helsinki. This article does not contain any animal-based studies performed by none of the authors.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available on reasonable request.

Open access

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Lingling Han http://orcid.org/0000-0002-1032-2842

REFERENCES

1 International Diabetes Federation (IDF). IDF diabetes atlas ninth edition, 2019. Available: https://diabetesatlas.org/en/resources/
2 Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care 2003;26:226–9.
3 Liu L, Wu X, Liu L, et al. Prevalence of diabetic retinopathy in mainland China: a meta-analysis. PLoS One 2012;7:e45264.
4 Yang Q-H, Zhang Y, Zhang X-M, et al. Prevalence of diabetic retinopathy, proliferative diabetic retinopathy and non-proliferative diabetic retinopathy in Asian T2DM patients: a systematic review and meta-analysis. Int J Ophthalmol 2019;12:202–11.
5 American Diabetes Association. 11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42:S124–38.
6 Strzałkowski M, Karczewska-Kupczewska M, Adamska A, et al. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation. Int J Obes 2013;37:1386–90.
7 Gao R-Y, Hsu B-G, Wu D-A, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res 2014;2014:1–6.
8 Zhang W, Chu S, Ding W, et al. Serum fibroblast growth factor 21 levels are positively associated with metabolic syndrome in patients with type 2 diabetes. Int J Endocrinol 2019;2019:1–8.
9 Zhang W, Chu S, Ding W, et al. Serum fibroblast growth factor 21 is independently associated with acute myocardial infarction. PLoS One 2015;10:e0129791.
10 Zhang X, Hu Y, Zeng H, et al. Serum fibroblast growth factor 21 levels is associated with lower extremity atherosclerotic disease in Chinese female diabetic patients. Cardiovasc Diabetol 2015;14:32.
11 American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012;35 Suppl 1:S11–63.
12 Wilkinson CP, Ferris FL, Klein RE, et al. Proposed International clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–82.
13 Zhang X, Yeung DCY, Karpisek M, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008;57:1246–53.
14 Chen C, Cheung BMI, Tao AWK, et al. High plasma level of fibroblast growth factor 21 is an independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 2011;34:2113–5.
15 Knott ME, Minnata JN, Roulet L, et al. Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer. J Mol Biomark Diagn 2016;1: doi:10.4172/2155-9929.1000.2015. [Epub ahead of print: 20 05 2016].
16 Leske MC, Wu S-Y, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados eye studies. Ophthalmology 2003;112:739–80.
17 Pang C, Jia L, Jiang S, et al. Determination of diabetic retinopathy prevalence and associated risk factors in Chinese diabetic and pre-diabetic subjects: Shanghai diabetic complications study. Diabetes Metab Res Rev 2012;28:276–83.
18 Lin Y, Xiao Y-cheng, Zhu H, et al. Serum fibroblast growth factor 21 levels are correlated with the severity of diabetic retinopathy. J Diabetes Res 2014;2014:1–6.
18 Mousavi Z, Bonakdaran S, Sahebkar A, et al. The relationship between serum levels of fibroblast growth factor 21 and diabetic retinopathy. *Excli J* 2017;16:1249–56.

19 Yaghoobi G, Shokoohi-Rad S, Jafarzadeh H, et al. Serum fibroblast growth factor 21 in patients with and without pterygia. *J Ophthalmic Vis Res* 2020;15:38–44.

20 Ong K-L, Januszewski AS, O’Connell R, et al. Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the fenofibrate intervention and event lowering in diabetes study. *Diabetologia* 2015;58:2035–44.

21 Esteghamati A, Momeni A, Abdollahi A, et al. Serum fibroblast growth factor 21 concentrations in type 2 diabetic retinopathy patients. *Ann Endocrinol* 2016;77:586–92.

22 Jung C-H, Jung S-H, Kim B-Y, et al. The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus. *J Diabetes Complications* 2017;31:134–40.

23 Yang M, Zhang L, Wang C, et al. Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. *PLoS One* 2012;7:e48392.

24 Rusu CC, Racasan S, Kacso IM, et al. The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients. *Int Urol Nephrol* 2017;49:517–23.

25 Holland WL, Adams AC, Brozinick JT, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. *Cell Metab* 2013;17:790–7.

26 Lin Z, Tian H, Lam KSL, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. *Cell Metab* 2013;17:779–89.

27 Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice. *Circulation* 2015;131:1861–71.

28 Pan X, Shao Y, Wu F, et al. FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2/Angiotensin-(1-7) Axis in Mice. *Cell Metab* 2018;27:1323–37.

29 Ying L, Li N, He Z, et al. Fibroblast growth factor 21 ameliorates diabetes-induced endothelial dysfunction in mouse aorta via activation of the CaMKK2/AMPKα signaling pathway. *Cell Death Dis* 2019;10:665.